This article is more than 5 years old. Information may no longer be current.

Assurex expands reach of genetic test

Assurex Health Inc, recently announced the addition of two drug classes to its GeneSight Psychotropic test, expanding the range of options for health care providers making medication decisions for patients with psychiatric and behavioral disorders.

With the two new drug classes, 17 FDA-approved medications and 4 clinically-validated genes, GeneSight Psychotropic covers 97% of prescriptions for depression, anxiety, bipolar disorder and schizophrenia.

Using GeneSight to aid treatment decisions has reduced annual health care costs by more than $2,500 per patient each year, according to a company press release.

In a recent study of the genetic test, medication costs decreased by more than $1,000 per patient per year, treatment adherence significantly improved and the number of co-prescribed medications decreased.

“Assurex Health's addition of more medicines, new relevant genes and enhanced reporting makes GeneSight Psychotropic the best-in-class tool to assist health care providers in choosing genetically appropriate medications for their patients. It is invaluable when selecting a medication, changing dose, or augmenting therapy,” Gina Drosos, Assurex Health CEO, said in the release. “By enhancing the science underlying the GeneSight test, Assurex Health can improve health outcomes and provide cost savings for patients, providers and payors.”